wiki.sine.space | sinespace

Difference between revisions of "Alvage therapy with BRAF inhibitors for recurrent pleomorphic xanthoastrocytoma: a retrospective"

From wiki.sine.space
Jump to: navigation, search
m
m
 
Line 1: Line 1:
Sievert AJ, Lang SS, Boucher KL, Madsen PJ, Slaunwhite E, Choudhari N, Kellet M, Storm PB, Resnick AC: Paradoxical [http://shop.gmynsh.com/comment/html/?291341.html Significance of LAT1 inpatients with biliary tract cancer. LAT1 expression was] activation and RAF inhibitor resistance of BRAF protein kinase fusions characterizing pediatric astrocytomas. J Clinical Oncol Off J Am Soc Clinical Oncol 2013, 31:51 448. Nazarian R, Shi H, Wang Q, Kong X, Koya RC, Lee H, Chen Z, Lee MK, Attar N, Sazegar H, Chodon T, Nelson SF, McArthur G, Sosman JA, Ribas A, Lo R: Melanomas obtain resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature 2010, 468:973?77. Flaherty KT, Infante JR, Daud A, Gonzalez R, Kefford RF, Sosman J, Hamid O, Schuchter L, Cebon J, Ibrahim N, Kudchadkar R, Burris HA, Falchook G, Algazi A, Lewis K, Extended GV, Puzanov I, Lebowitz P, Singh A, Small S, Sun P, Allred A, Ouellet D, Kim KB, Petel K, Weber J: Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations.Alvage therapy with BRAF inhibitors for recurrent pleomorphic xanthoastrocytoma: a retrospective case series. J Neuro-Oncol 2013, 114:237?40. ten. Rush S, Foreman N, Liu A: Brainstem ganglioglioma effectively treated with vemurafenib. J Clinical Oncol Off J Am Soc Clinical Oncol 2013, 31:e159 160. 11. Bautista F, Paci A, Minard-Colin V, Dufour C, Grill J, Lacroix L, Varlet P, Valteau-Couanet D, Geoerger B: Vemurafenib in pediatric individuals with BRAFV600E mutated high-grade gliomas. Pediatr Blood Cancer 2013. doi:ten.1002/pbc.24891. 12. Frattini V, Trifonov V, Chan JM, Castano A, Lia M, Abate F, Keir ST, Ji AX, Zoppoli P, [https://www.ncbi.nlm.nih.gov/pubmed/26162776 PubMed ID:https://www.ncbi.nlm.nih.gov/pubmed/26162776] Niola F, Danussi C, Dolgalev I, Porrati P, Pellegatta S, Heguy S, Gupta G, Pisapia DJ, Canoll P, Bruce JN, Mclendon RE, Yan H, Aldape K, 17. 13.14.15.16.18.19.20.Finocchiaro G, Mikkelsen T, Prive GG, Bigner DD, Lasorella A, Rabadan R, Iavarone A: The integrated landscape of driver genomic alterations in glioblastoma. Nat Genet 2013, 45:1141?149. Sievert AJ, Lang SS, Boucher KL, Madsen PJ, Slaunwhite E, Choudhari N, Kellet M, Storm PB, Resnick AC: Paradoxical activation and RAF inhibitor resistance of BRAF protein kinase fusions characterizing pediatric astrocytomas. Proc Natl Acad Sci U S A 2013, 110:5957?962. Sosman JA, Kim KB, Schuchter L, Gonzalez R, Pavlick AC, Weber JS, McArthur GA, Hutson TE, Moschos SJ, Flaherty KT, Hersey P, Kefford R, Lawrence D, Puzanov I, Lewis KD, Amaravadi RK, Chmielowski B, Lawrence HJ, Shyr Y, Ye F, Li J, Nolop KB, Lee RJ, Joe AK, Ribas A: Survival in BRAF V600-mutant sophisticated melanoma treated with vemurafenib. N Engl J Med 2012, 366:707?14. Callahan MK, Rampal R, Harding JJ, Klimek VM, Chung YR, Merghoub T, Wolchok JD, Solit DB, Rosen N, Abdel-Wahab O, Levine RL, Chapman PB: Progression of RAS-mutant leukemia in the course of RAF inhibitor therapy. N Engl J Med 2012, 367:2316?321. Su F, Viros A, Milagre C, Trunzer K, Bollag G, Spleiss O, Reis-Filho JS, Kong X, Koya RC, Flaherty KT, Chapman PB, Kim MJ, Hayward R, Martin M, Yang H, Wang Q, Hilton H, Hang JS, Noe J, Lambros M, Geyer F, Dhomen N, Niculescu-Duvaz I, Zambon A, Niculescu-Duvaz D, Preece N, Robert L, Otte NJ, Mok S, Kee D: RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors.
+
Sievert AJ, Lang SS, Boucher KL, Madsen PJ, Slaunwhite E, Choudhari N, Kellet M, Storm PB, Resnick AC: Paradoxical activation and RAF [http://www.shuyigo.com/comment/html/?856666.html Compact number of time points and only to get a small number] inhibitor resistance of BRAF protein kinase fusions characterizing pediatric astrocytomas. Andrews MC, Behren A, Chionh F, Mariadason J, Vella LJ, Do H, [https://www.ncbi.nlm.nih.gov/pubmed/26104484 PubMed ID:https://www.ncbi.nlm.nih.gov/pubmed/26104484] Dobrovic A, Tebbutt N, Cebon J: BRAF inhibitor-driven tumor proliferation within a KRAS-mutated colon carcinoma just isn't overcome by MEK1/2 inhibition. J Clinical Oncol Off J Am Soc Clinical Oncol 2013, 31:51 448. Nazarian R, Shi H, Wang Q, Kong X, Koya RC, Lee H, Chen Z, Lee MK, Attar N, Sazegar H, Chodon T, Nelson SF, McArthur G, Sosman JA, Ribas A, Lo R: Melanomas obtain resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature 2010, 468:973?77. Flaherty KT, Infante JR, Daud A, Gonzalez R, Kefford RF, Sosman J, Hamid O, Schuchter L, Cebon J, Ibrahim N, Kudchadkar R, Burris HA, Falchook G, Algazi A, Lewis K, Long GV, Puzanov I, Lebowitz P, Singh A, Little S, Sun P, Allred A, Ouellet D, Kim KB, Petel K, Weber J: Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations.Alvage therapy with BRAF inhibitors for recurrent pleomorphic xanthoastrocytoma: a retrospective case series. J Neuro-Oncol 2013, 114:237?40. 10. Rush S, Foreman N, Liu A: Brainstem ganglioglioma successfully treated with vemurafenib. J Clinical Oncol Off J Am Soc Clinical Oncol 2013, 31:e159 160. 11. Bautista F, Paci A, Minard-Colin V, Dufour C, Grill J, Lacroix L, Varlet P, Valteau-Couanet D, Geoerger B: Vemurafenib in pediatric sufferers with BRAFV600E mutated high-grade gliomas. Pediatr Blood Cancer 2013. doi:ten.1002/pbc.24891. 12. Frattini V, Trifonov V, Chan JM, Castano A, Lia M, Abate F, Keir ST, Ji AX, Zoppoli P, [https://www.ncbi.nlm.nih.gov/pubmed/26162776 PubMed ID:https://www.ncbi.nlm.nih.gov/pubmed/26162776] Niola F, Danussi C, Dolgalev I, Porrati P, Pellegatta S, Heguy S, Gupta G, Pisapia DJ, Canoll P, Bruce JN, Mclendon RE, Yan H, Aldape K, 17. 13.14.15.16.18.19.20.Finocchiaro G, Mikkelsen T, Prive GG, Bigner DD, Lasorella A, Rabadan R, Iavarone A: The integrated landscape of driver genomic alterations in glioblastoma. Nat Genet 2013, 45:1141?149. Sievert AJ, Lang SS, Boucher KL, Madsen PJ, Slaunwhite E, Choudhari N, Kellet M, Storm PB, Resnick AC: Paradoxical activation and RAF inhibitor resistance of BRAF protein kinase fusions characterizing pediatric astrocytomas. Proc Natl Acad Sci U S A 2013, 110:5957?962. Sosman JA, Kim KB, Schuchter L, Gonzalez R, Pavlick AC, Weber JS, McArthur GA, Hutson TE, Moschos SJ, Flaherty KT, Hersey P, Kefford R, Lawrence D, Puzanov I, Lewis KD, Amaravadi RK, Chmielowski B, Lawrence HJ, Shyr Y, Ye F, Li J, Nolop KB, Lee RJ, Joe AK, Ribas A: Survival in BRAF V600-mutant sophisticated melanoma treated with vemurafenib. N Engl J Med 2012, 366:707?14. Callahan MK, Rampal R, Harding JJ, Klimek VM, Chung YR, Merghoub T, Wolchok JD, Solit DB, Rosen N, Abdel-Wahab O, Levine RL, Chapman PB: Progression of RAS-mutant leukemia in the course of RAF inhibitor remedy. N Engl J Med 2012, 367:2316?321.

Latest revision as of 03:50, 5 May 2019

Sievert AJ, Lang SS, Boucher KL, Madsen PJ, Slaunwhite E, Choudhari N, Kellet M, Storm PB, Resnick AC: Paradoxical activation and RAF Compact number of time points and only to get a small number inhibitor resistance of BRAF protein kinase fusions characterizing pediatric astrocytomas. Andrews MC, Behren A, Chionh F, Mariadason J, Vella LJ, Do H, PubMed ID:https://www.ncbi.nlm.nih.gov/pubmed/26104484 Dobrovic A, Tebbutt N, Cebon J: BRAF inhibitor-driven tumor proliferation within a KRAS-mutated colon carcinoma just isn't overcome by MEK1/2 inhibition. J Clinical Oncol Off J Am Soc Clinical Oncol 2013, 31:51 448. Nazarian R, Shi H, Wang Q, Kong X, Koya RC, Lee H, Chen Z, Lee MK, Attar N, Sazegar H, Chodon T, Nelson SF, McArthur G, Sosman JA, Ribas A, Lo R: Melanomas obtain resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature 2010, 468:973?77. Flaherty KT, Infante JR, Daud A, Gonzalez R, Kefford RF, Sosman J, Hamid O, Schuchter L, Cebon J, Ibrahim N, Kudchadkar R, Burris HA, Falchook G, Algazi A, Lewis K, Long GV, Puzanov I, Lebowitz P, Singh A, Little S, Sun P, Allred A, Ouellet D, Kim KB, Petel K, Weber J: Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations.Alvage therapy with BRAF inhibitors for recurrent pleomorphic xanthoastrocytoma: a retrospective case series. J Neuro-Oncol 2013, 114:237?40. 10. Rush S, Foreman N, Liu A: Brainstem ganglioglioma successfully treated with vemurafenib. J Clinical Oncol Off J Am Soc Clinical Oncol 2013, 31:e159 160. 11. Bautista F, Paci A, Minard-Colin V, Dufour C, Grill J, Lacroix L, Varlet P, Valteau-Couanet D, Geoerger B: Vemurafenib in pediatric sufferers with BRAFV600E mutated high-grade gliomas. Pediatr Blood Cancer 2013. doi:ten.1002/pbc.24891. 12. Frattini V, Trifonov V, Chan JM, Castano A, Lia M, Abate F, Keir ST, Ji AX, Zoppoli P, PubMed ID:https://www.ncbi.nlm.nih.gov/pubmed/26162776 Niola F, Danussi C, Dolgalev I, Porrati P, Pellegatta S, Heguy S, Gupta G, Pisapia DJ, Canoll P, Bruce JN, Mclendon RE, Yan H, Aldape K, 17. 13.14.15.16.18.19.20.Finocchiaro G, Mikkelsen T, Prive GG, Bigner DD, Lasorella A, Rabadan R, Iavarone A: The integrated landscape of driver genomic alterations in glioblastoma. Nat Genet 2013, 45:1141?149. Sievert AJ, Lang SS, Boucher KL, Madsen PJ, Slaunwhite E, Choudhari N, Kellet M, Storm PB, Resnick AC: Paradoxical activation and RAF inhibitor resistance of BRAF protein kinase fusions characterizing pediatric astrocytomas. Proc Natl Acad Sci U S A 2013, 110:5957?962. Sosman JA, Kim KB, Schuchter L, Gonzalez R, Pavlick AC, Weber JS, McArthur GA, Hutson TE, Moschos SJ, Flaherty KT, Hersey P, Kefford R, Lawrence D, Puzanov I, Lewis KD, Amaravadi RK, Chmielowski B, Lawrence HJ, Shyr Y, Ye F, Li J, Nolop KB, Lee RJ, Joe AK, Ribas A: Survival in BRAF V600-mutant sophisticated melanoma treated with vemurafenib. N Engl J Med 2012, 366:707?14. Callahan MK, Rampal R, Harding JJ, Klimek VM, Chung YR, Merghoub T, Wolchok JD, Solit DB, Rosen N, Abdel-Wahab O, Levine RL, Chapman PB: Progression of RAS-mutant leukemia in the course of RAF inhibitor remedy. N Engl J Med 2012, 367:2316?321.